This report is no longer available. Click here to view our current reports or contact us to discuss a custom report.
If you have previously purchased this report then please use the download links on the right to download the files.
1. | EXECUTIVE SUMMARY |
1.1. | COVID-19 is an infectious disease caused by the novel coronavirus SARS-CoV-2 |
1.2. | Overview of the technologies for COVID-19 diagnostics |
1.3. | Performance comparison of different technologies for COVID-19 diagnostics |
1.4. | Molecular diagnostics sits at the heart of COVID-19 diagnostics |
1.5. | US companies lead the COVID-19 molecular diagnostics test |
1.6. | Real-Time PCR/ Quantitative PCR (qPCR) |
1.7. | Reverse Transcription-Polymerase Chain Reaction (RT-PCR) |
1.8. | Genetic testing for COVID-19 |
1.9. | Amplification: isothermal amplification as alternative |
1.10. | Digital PCR (dPCR) for COVID-19 diagnostics are being developed |
1.11. | Antibody and antigen test |
1.12. | Lateral flow assays enable rapid tests of COVID-19 |
1.13. | Antibody and antigen test: enzyme-linked immunosorbent assay (ELISA) |
1.14. | Highly sensitive and specific immunoassays: big equipment and longer testing time |
1.15. | Countries are struggling to find good quality rapid test kits |
1.16. | Chinese companies dominate the LFAs market for COVID-19 test |
1.17. | Key trends in COVID-19 diagnostics innovations |
1.18. | Point-of-Care Molecular Diagnostics accelerate the sample-to-answer time for COVID-19 diagnostics |
1.19. | Isothermal amplification will replace PCR? |
1.20. | Hybrid diagnostics assays: trade-off between performance, speed and price |
1.21. | Omit RNA extraction? |
1.22. | CRISPR-Cas based diagnostics |
1.23. | The role of DNA sequencing in COVID-19 detection |
1.24. | Combine of PCR and DNA sequencing for high through-put COVID-19 diagnostics |
1.25. | Market landscape for post COVID-19 |
2. | INTRODUCTION |
2.1. | What are infectious diseases? |
2.2. | Historically infectious diseases have been the leading cause of death |
2.3. | Infectious diseases may lead to a pandemic |
2.4. | COVID-19 is an infectious disease caused by the novel coronavirus SARS-CoV-2 |
2.5. | COVID-19 as a pandemic |
2.6. | Epidemiology of Covid-19 |
2.7. | Main techniques to diagnose infectious diseases |
2.8. | Microscopy and culture growth methods are not suitable for fast virus detection |
2.9. | Overview of the technologies for COVID-19 diagnostics |
2.10. | Biomarkers for COVID-19 |
2.11. | RNA genome as biomarker |
2.12. | Mass testing for COVID-19 |
2.13. | Sample-to-answer time for different diagnostic technologies |
2.14. | Sensitivity and specificity |
2.15. | Sensitivity and specificity for different diagnostic technologies |
2.16. | Performance comparison of different technologies for COVID-19 diagnostics |
2.17. | Key trends in COVID-19 diagnostics innovations |
3. | MOLECULAR DIAGNOSTICS IS THE GOLD STANDARD FOR COVID-19 DIAGNOSTICS |
3.1.1. | Molecular diagnostics sits at the heart of COVID-19 diagnostics |
3.1.2. | US companies lead the COVID-19 molecular diagnostics test |
3.1.3. | Working flow of MDx devices |
3.1.4. | Detection methods are being used commercially |
3.1.5. | Fluorescence detection is the top option |
3.1.6. | Electrochemical detection: label free |
3.2. | Technology: Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) |
3.2.1. | Polymerase chain reaction (PCR): Introduction |
3.2.2. | Polymerase chain reaction (PCR): Process |
3.2.3. | Real-time reverse transcription-polymerase chain reaction is the most popular choice |
3.2.4. | Real-Time PCR/ Quantitative PCR (qPCR) |
3.2.5. | Reverse Transcription-Polymerase Chain Reaction (RT-PCR) |
3.2.6. | qRT-PCR is the gold standard to diagnose COVID-19 |
3.2.7. | RNA extraction is a bottleneck for many laboratories |
3.2.8. | Droplet Digital PCR (ddPCR, Bio-Rad) |
3.2.9. | Digital PCR (dPCR) for COVID-19 diagnostics are being developed |
3.2.10. | Key players for PCR devices |
3.2.11. | Key players for PCR reagents/consumables |
3.2.12. | Market share for PCR equipment For COVID-19 diagnostics |
3.3. | Technology: Isothermal amplification |
3.3.1. | Isothermal amplification of nucleic acids |
3.3.2. | Overview of Isothermal Amplification Technologies I |
3.3.3. | Overview of Isothermal Amplification Technologies II |
3.3.4. | Which is the future: isothermal amplification or PCR? |
3.3.5. | Isothermal amplification based COVID-19 diagnostics |
3.4. | Technology: DNA sequencing |
3.4.1. | The role of DNA sequencing in COVID-19 detection |
3.4.2. | DNA sequencing |
3.4.3. | DNA sequencing technology: first generation |
3.4.4. | Capillary Electrophoresis DNA sequencers |
3.4.5. | Next generation sequencing (NGS) |
3.4.6. | Second generation sequencing workflows (Illumina) |
3.4.7. | Key players for second generation sequencing |
3.4.8. | 3rd generation sequencing |
3.4.9. | Key players for third generation sequencing |
3.4.10. | Cost of DNA sequencing is dropping |
3.4.11. | Future trends and opportunities |
3.4.12. | Lists of qRT-PCR test kits with approval for COVID-19 diagnostics (excl. POC MDx) (1) |
3.4.13. | Lists of qRT-PCT test kits with approval for COVID-19 diagnostics (excl. POC MDx) (2) |
3.4.14. | Lists of qRT-PCT test kits with approval for COVID-19 diagnostics (excl. POC MDx) (3) |
3.4.15. | Lists of qRT-PCT test kits with approval for COVID-19 diagnostics (excl. POC MDx) (4) |
3.4.16. | Lists of qRT-PCT test kits with approval for COVID-19 diagnostics (excl. POC MDx) (5) |
3.4.17. | Lists of qRT-PCT test kits with approval for COVID-19 diagnostics (excl. POC MDx) (6) |
3.4.18. | Roche molecular systems: Cobas SARS-CoV-2 |
3.4.19. | BGI Genomics: Real-Time SARS-CoV-2 Test |
3.4.20. | PerkinElmer: New Coronavirus Nucleic Acid Detection Kit |
3.4.21. | Quest Diagnostic: SARS-CoV-2 RNA, qRT-PCR |
3.4.22. | Quidel: Lyra SARS-CoV-2 Assay |
3.4.23. | Primerdesign COVID-19 genesig Real-Time PCR assay |
3.4.24. | Gnomegen: COVID-19 RT-Digital PCR Detection Kit |
3.4.25. | Vision Medicals: SARS-CoV-2 Clinical Sequencing assay |
4. | EMERGING MOLECULAR DIAGNOSTICS AT POINT-OF-CARE |
4.1. | Miniaturised devices enable molecular diagnostics at point-of-care |
4.2. | Molecular diagnostics is moving to point-of-care |
4.3. | The Rise of Point-of-Care Molecular Diagnostics |
4.4. | Point-of-Care Molecular Diagnostics accelerate the sample-to-answer time for COVID-19 diagnostics |
4.5. | What constitutes a Point-of-Care MDx test? |
4.6. | What it takes to win in point-of-care molecular diagnostics |
4.7. | The value of point-of-care testing |
4.8. | The importance of POC biosensors and comparison to centralised testing |
4.9. | Examples of POC MDx devices |
4.10. | Costing of test kits for POC MDx devices |
4.11. | POC MDx: Atlas io system |
4.12. | POC MDx: Cobas Liat |
4.13. | POC MDx: Alere i |
4.14. | POC MDx: Alere q Analyzer |
4.15. | POC MDx: Spartan Cube |
4.16. | POC MDx: FilmArray 2.0 |
4.17. | POC MDx: PanNAT system |
4.18. | POC MDx: GeneXpert Omni |
4.19. | POC MDx: Spartan Cube |
4.20. | POC MDx: Q-POC |
4.21. | Additional POC MDx: systems |
4.22. | Lists of POC MDx kits with approval for COVID-19 diagnostics |
4.23. | Cepheid: Xpert® Xpress SARS-CoV-2 |
4.24. | Abbott: ID NOW™ COVID-19 rapid test |
4.25. | Technology for ID NOW™ COVID-19 rapid test |
4.26. | bioMérieux: BioFire COVID-19 Test |
4.27. | DiaSorin Molecular: Simplexa COVID-19 Direct assay |
5. | IMMUNOASSAYS |
5.1. | Immunoassays |
5.2. | Antibody and antigen test |
5.3. | Lateral flow assays (LFAs) is one of the main commercialised methods to detect infectious disease |
5.4. | Lateral flow assays is widely used for various applications |
5.5. | Biomarker and bioreceptor: antigens and antibodies |
5.6. | Mechanisms of lateral flow immunoassays |
5.7. | Materials and manufacturing of lateral flow assay strips |
5.8. | Point-of-care molecular diagnostic (POC MDx) is taking over the infectious disease market from lateral flow assays |
5.9. | MDx or LFAs |
5.10. | Lateral flow assays enable rapid tests of COVID-19 |
5.11. | Enzyme-linked immunosorbent assay (ELISA) |
5.12. | Antigenic tests |
5.13. | Serological test |
5.14. | Chinese companies dominate the LFAs market for COVID-19 test |
5.15. | Countries are struggling to find good quality rapid test kits |
5.16. | Rapid tests purchased by Spain |
5.17. | Rapid tests purchased by the UK |
5.18. | List of LAFs test kits with approval for COVID-19 diagnostics (1) |
5.19. | List of LAFs test kits with approval for COVID-19 diagnostics (2) |
5.20. | List of LAFs test kits with approval for COVID-19 diagnostics (3) |
5.21. | Cellex: qSARS-CoV-2 IgG/IgM Rapid Test |
5.22. | Roche: Elecsys Anti-SARS-CoV-2 serology test |
5.23. | Abbott: serology test |
5.24. | Bio-Rad: Platelia SARS-CoV-2 Total Ab assay |
5.25. | Quidel: Sofia 2 SARS Antigen FIA Test |
6. | HYBRID DIAGNOSTICS SYSTEMS |
6.1. | Hybrid diagnostics assays: trade-off between performance, speed and price |
6.2. | Lateral flow assays to detect DNA biomarkers |
6.3. | MDx with electrochemical detection without label |
6.4. | Luminex Molecular Diagnostics: NxTAG CoV Extended Panel Assay |
6.5. | Luminex: xMAP Technology |
6.6. | Mesa Biotech: Accula SARS-Cov-2 Test |
6.7. | CRISPR-Cas based diagnostics |
6.8. | CRISPR-Cas based diagnostics work flow |
6.9. | Competition of CRISPR-Cas based diagnostics |
6.10. | Other player in CRISPR technology for COVID-19 testing |
6.11. | Combine of PCR and DNA sequencing for high through-put COVID-19 diagnostics |
6.12. | Octant: next generation sequencing for mass COVID-19 |
6.13. | BillionToOne: sanger sequencing for large scale COVID-19 testing |
7. | OTHER TECHNOLOGY INNOVATIONS |
7.1. | COVID-19 diagnostics via smell |
7.2. | COVID-19 diagnostics via breath |
7.3. | COVID-19 diagnostics and monitoring via biological patterns |
7.4. | AI for COVID-19 diagnostics |
7.5. | AI for COVID-19: Key players |
7.6. | AI for COVID-19: Infervision |
7.7. | AI for COVID-19: Other companies |
7.8. | COVID-19 detection AI: Algorithm comparison |
Slides | 182 |
---|